Content Type: Article

  • Data protection: Companies also face fines for violations by “unknown” persons

    Data protection: Companies also face fines for violations by “unknown” persons

    ARTICLE

    Data protection: Companies also face fines for violations by “unknown” persons

    February 28, 2024

    Read time: 2 min

    Key takeaways
    Overview

    Companies can expect fines for data protection violations even without an identifiable culprit or breach of supervision. It is sufficient if the company should have recognized that the data processing was unlawful.

    Dr. Philip Uecker discusses the consequences of the latest court rulings in the article “Data protection: companies face fines even for breaches by “unknown persons””, published on “Markt und Mittelstand”.

    In depth
    Authors

    Dr. Philip Uecker

    Associate

    Düsseldorf

    More insights

  • Change Healthcare Security Incident – Practicable Next Steps for Impacted Customers

    Change Healthcare Security Incident – Practicable Next Steps for Impacted Customers

    ARTICLE / CLIENT ALERT

    Change Healthcare Security Incident – Practicable Next Steps for Impacted Customers

    February 28, 2024

    Read time: 5 min

    Key takeaways
    Overview

    The Change Healthcare ransomware attack presents potentially significant ramifications for hospitals, health systems, pharmacies and others that rely on the organization’s tools for healthcare payment, revenue cycle management, medication fulfillment and other health-related functions. This report reviews the impact of the attack as of February 28, 2024, and outlines next steps for organizations impacted by the incident and related business interruption.

    In depth

    Change Healthcare, a healthcare technology company that is a business unit of Optum and owned by UnitedHealth Group, announced on February 21, 2024, that it was experiencing enterprise-wide connectivity issues and service application interruptions (the Incident). Change Healthcare offers, among other services, application tools for healthcare payment and revenue cycle management to healthcare provider customers. According to media reports, the Incident has been attributed to the ALPHV Blackcat ransomware as a service (Raas).

    The ramifications of the Incident are potentially significant:

    • The Incident has disrupted operations at pharmacies and health systems across the US that rely on Change Healthcare tools for healthcare payment and revenue cycle management.
    • The American Hospital Association (AHA) recommended on February 24, 2024, that all healthcare organizations that “were disrupted or are potentially exposed by this incident consider disconnection from applications specified by Change Healthcare that remain unavailable due to this cyberattack.”
    • According to UnitedHealth Group, more than 90% of US pharmacies have set up modified electronic claims processing workarounds to avoid disrupted systems, and the remainder have established offline processing systems.
    • If the Incident is determined to have compromised patient protected health information or personal information, impacted organizations may have breach notification obligations under the Health Insurance Portability and Accountability Act (HIPAA) and/or state breach notification laws and could face regulatory investigations or privacy-related civil litigation.

    According to a February 27, 2024, #StopRansomware: ALPHV Blackcat joint Cybersecurity Advisory released by the Cybersecurity & Infrastructure Security Agency (CISA) and the Federal Bureau of Investigation (FBI), the FBI has identified more than 1,000 victims worldwide of ALPHV Blackcat ransomware and/or data extortion incidents. The healthcare sector has been the most commonly targeted.

    Although the initial attack vector is not yet publicly known, Health Information Sharing and Analysis Center (Health-ISAC) said in a threat intelligence bulletin on February 26, 2024, that – based on information published by intelligence firm RedSense – Change Healthcare (and other organizations) may have fallen victim to exploitation of the recently announced ConnectWise ScreenConnect vulnerabilities (CVE-2024-1708 and CVE-2024-1709). According to Health-ISAC, RedSense anticipates that more organizations will be compromised because the ScreenConnect exploit is simple to execute, and that additional victims may be identified in the coming days.

    Actionable next steps for impacted Change Healthcare customers include (but are not limited to) the following:

    • Communicating with payors regarding payment workarounds to bypass disrupted Change Healthcare applications.
    • Monitoring the Change Healthcare Incident update website for relevant updates.
    • Monitoring AHA advisories for relevant updates and recommendations, including recommendations regarding connectivity to Change Healthcare applications.
    • Reviewing Health-ISAC recommendations, including recommendations regarding maintaining network connectivity with UnitedHealth Group, Optum and UnitedHealthcare, and monitoring known indicators of compromise to identify compromised systems and/or prevent unauthorized access.
    • Developing a set of security- and Incident-related questions or criteria for Change Healthcare in order to reestablish connectivity with Change Healthcare systems (e.g., what assurances can be provided that the risk has been contained and remediated? What security improvements have been implemented to help ensure similar incidents do not occur again?).
    • Reviewing CISA recommendations to reduce the likelihood and impact of ALPHV Blackcat ransomware and data extortion incidents.
    • Monitoring Healthcare Financial Management Association (HFMA) recommendations and updates with respect to potential claims of processing- and payment-related cashflow interruptions.
    • Monitoring US Department of Health and Human Services (HHS) channels for information related to AHA’s request that HHS offer guidance on how providers can access Medicare advance or accelerated payments to smooth cashflow issues.
    • Potentially notifying cyber carriers and other applicable insurers of any business interruptions and of a potential security incident, even if the potential impacts of the Incident are not yet fully determined.
    • Reviewing HIPAA compliance programs, including (among others) written policies and procedures and security risk analyses, in preparation for potential breach notifications, regulatory investigations, and/or privacy-related civil litigation.

    For assistance regarding health information data privacy or security compliance or incident response matters, please contact Ryan Higgins (rshiggins@mwe.com), Ed Zacharias (ezacharias@mwe.com) or Stephen Bernstein (sbernstein@mwe.com).

    Authors
    More insights

  • DOJ and OIG Actions: 2023 Enforcement Trends Recap

    DOJ and OIG Actions: 2023 Enforcement Trends Recap

    ARTICLE / CLIENT ALERT

    DOJ and OIG Actions: 2023 Enforcement Trends Recap

    February 28, 2024

    Read time: 9 min

    Key takeaways
    Overview

    This report reviews notable areas for government enforcement actions during 2023 that were discussed in our monthly Healthcare Regulatory Check-Up reports. In the past year, we saw the relevant federal government enforcement agencies – the Department of Justice (DOJ) and Department of Health and Human Services Office of Inspector General (OIG) – resolve a number of actions with healthcare organizations under the False Claims Act (FCA) and related criminal authorities. Healthcare organizations should consider using this information to help define compliance activities, such as risk assessments, auditing and monitoring.

    In depth

    In fiscal year (FY) 2023, ending September 30, DOJ reported $2.68 billion in FCA payments, with $1.8 billion attributable to healthcare cases. This healthcare amount represents about 67% of the total FCA payments, which is a decline from recent years. (In 2021 and 2022, healthcare settlements were 90% and 80% of total FCA payments, respectively.) The number of new healthcare FCA cases filed in FY 2023 also declined slightly when compared to prior years, with 348 filed by relators and 94 filed by the government. Even still, the total number represents between eight and nine new healthcare FCA cases filed each week.

    Notable trends and topics include:

    Anti-Kickback Statute (AKS) Allegations Are Frequent and Far Reaching

    AKS allegations have long been one of the most common subjects of FCA and criminal actions. A significant portion of FCA settlement payments each year concern AKS allegations. The scope of the AKS is broad, touching on virtually all healthcare organizations’ financial relationships with each other and with their employees, contractors, vendors, referral sources and patients.

    We found examples of enforcement actions along a wide spectrum of allegations, including:

    • A manufacturer giving physicians lavish meals, trips and entertainment to induce ordering the manufacturer’s products or making referrals to another provider
    • Entities providing employed, mid-level practitioners to referring physicians at no cost or below cost
    • An electronic health records company paying current customers to recommend their product to others
    • Specialists allocating non-fair market value (FMV) payments to referring physicians in the context of co-management agreements
    • A skilled nursing facility paying hospital administrators to induce referrals
    • Entities paying non-FMV for space rental
    • Labs paying physicians through management service organizations (MSOs) to induce referrals or for specimen-collection services at above FMV
    • Entities paying above FMV for physician consulting or medical director arrangements
    • Entities routinely waiving Medicare beneficiary co-payments

    The Return of the Stark Law

    After somewhat of a hiatus, 2023 saw a notable increase in FCA matters, including Physician Self-Referral Law (known as the Stark Law) allegations alongside AKS allegations. Several organizations entered into FCA settlements for these issues, some of which were precipitated by the organization self-disclosing the issue to the government rather than as the result of a relator action. These settlements ranged from a few million dollars to $345 million, which is the largest-ever Stark Law-related FCA settlement.

    Given the Stark Law’s focus on physician compensation, most of these actions concerned allegations that a physician’s compensation violated the Stark Law because it took into account the volume or value of designated health services (DHS) referrals, such as by transferring a portion of its operating margin or prescription-drug profits to physicians, or that the compensation was above FMV. Cases also alleged above FMV space rental and equipment rental payments.

    Hospitals were not the only entities to settle Stark Law allegations:

    • A dermatology-management company that manages and operates numerous dermatology practices, surgical centers and pathology laboratories self-disclosed and paid $8.9 million to resolve AKS and Stark Law claims that former senior managers had agreed to raise the purchase price of 11 acquired dermatology practices as part of an arrangement where the providers agreed to refer services to company-affiliated entities after the acquisition of their practices.
    • A mobile cardiac positron emission tomography (PET) company and its owner, founder and CEO agreed to pay $85.48 million to resolve FCA allegations that the company paid referring cardiologists above FMV fees to supervise PET scans in violation of the AKS and Stark Law.

    Lab Testing, Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) and Telemedicine Are Under the Government’s Microscope

    Every month we found several examples of criminal and civil actions involving labs, DMEPOS companies and telemedicine providers. Often, the alleged misconduct involved all three types of entities. These actions frequently alleged kickbacks between the lab (usually for genetic or urine drug testing), marketers, DMEPOS companies (usually involving orthotic braces), and the telemedicine companies to procure prescriptions for such tests or DMEPOS. Some of these actions became national projects, such as Operation Double Helix, a coordinated federal law-enforcement action led by the Health Care Fraud Unit of the DOJ’s Criminal Division.

    In some cases, a single entity was alleged to be engaged in urine drug testing and DMEPOS misconduct. This occurred, for example, in a $6.5 million FCA settlement with a pain-management practice for billing for urine drug testing that was not medically necessary or relevant to their treatment of the patient, additional laboratory services that were not separately billable with the urine drug tests, and back braces that were medically unnecessary or otherwise ineligible for reimbursement.

    Other laboratory practices also have been the subject of scrutiny, including percentage-of-revenue commission payments to independent sales representatives and third-party marketing vendors, as well as the creation or processing of tests under a “blanket” or “standing” order or “custom profile” in which physicians allegedly did not specifically order each test for a particular patient.

    Medical Necessity and Medicare Billing Rules Also Can Create False Claims

    While there was much attention on AKS and Stark Law FCA actions in 2023, many FCA actions involved allegations of either a lack of medical necessity or failure to follow Medicare billing rules. These actions included the following allegations:

    • A hospital billing for concurrent surgeries
    • A device company advising customers to bill its devices under a code for which the devices did not qualify
    • A telehealth company enrolling patients in more-expensive cardiac monitoring device services than necessary
    • Numerous physician practices billing for medically unnecessary services
    • Entities billing for evaluation and management services that were not supported by the medical record
    • Providers performing multiple mole-removal procedures on patients on a single date, but billing for the services as if they were performed on separate dates
    • An imaging facility billing Medicare and Medicaid under its billing number for both the professional and technical components of imaging rendered by the hospital’s outpatient cancer screening center, after which the imaging facility then allegedly paid the center a portion of the Medicare- or Medicaid-reimbursed global fee for the technical services provided by the center (which was not enrolled in Medicare or Medicaid at the time and was thus ineligible to receive such payments)
    • A hospital billing for services under a physician’s name and national provider identifier when the services were furnished by mid-level practitioners
    • A physician practice billing Medicare for critical-care services provided to nursing-home residents when he provided only routine care

    COVID-19-Related FCA Enforcement Is on the Rise

    Finally, COVID-19-related FCA enforcement actions continue to increase. To date, more of the government’s COVID-19 enforcement has been criminally focused to reach the low-hanging fruit of improper billing to the Health Resources and Services Administration COVID-19 Uninsured Program (the HRSA Program). In April 2023, in one of the largest coordinated COVID-19 fraud actions to date, DOJ filed charged against 18 defendants in nine federal districts based on their alleged participation in various healthcare fraud schemes that exploited the COVID-19 pandemic and allegedly resulted in more than $490 million in COVID-19-related false billings to federal healthcare programs and the HRSA Program.

    Now that some time has passed since the height of the pandemic, FCA settlements and actions have begun to occur, such as the following:

    • A relatively small FCA settlement (for $300,479.58) with a billing company that billed for respiratory-pathogen panel tests at the direction of its lab client when the tests were not ordered by the physician listed on the claim
    • A settlement, between a hospital system and the United States, for $2 million plus additional contingent payments, to resolve FCA allegations of double billing when the hospital system billed the federal government for COVID-19 tests and either the State of Texas or the City of Houston for those same tests
    • A settlement with an urgent care company that agreed to pay more than $9.1 million to settle allegations that it had submitted false claims for medical services to Medicare, TRICARE and the HRSA Program for COVID-19 testing, as well as for physician-performed office visits (when a non-physician practitioner had actually conducted the visits) and up-coded office visits

    DOJ’s 2024 Priorities

    DOJ Principal Deputy Assistant Attorney General Brian Boynton discussed the fiscal year 2023 statistics and DOJ 2024 FCA priorities at the recent Federal Bar Association Qui Tam Section Conference. He described DOJ’s continued focus on healthcare fraud, specifically discussing their examination of financial relationships under the AKS and Stark Law and scrutinizing nursing homes, COVID-19 spending and participants in the Medicare Advantage Program, including providers, plans and vendors. He also mentioned DOJ’s interest in “third parties,” such as private equity investors, electronic health record software providers and coding consultants, and their impact on patient care delivery and federal program spending.

    Key Takeaways

    As has been the case for many years, FCA actions by the government and whistleblowers have resulted in defendants (1) making significant payments to the government and (2) incurring significant costs associated with investigating and defending these cases. Healthcare organizations can help reduce the risk of being subject to such actions by maintaining effective compliance programs that assess the organization’s risks, monitor and audit those risks, and encourage employees to report potential compliance concerns so they can be properly reviewed and remedied, if necessary.

    Authors

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Monica Wallace

    Partner

    Chicago

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    More insights

  • Google Moves to Dismiss Third Complaint Alleging Tying of Google Maps API Services

    Google Moves to Dismiss Third Complaint Alleging Tying of Google Maps API Services

    ARTICLE

    Google Moves to Dismiss Third Complaint Alleging Tying of Google Maps API Services

    Feb 28, 2024

    Read time: 5 min

    Key takeaways
    Overview
    In depth

    BACKGROUND

    Google LLC and Alphabet Inc. (Google) moved to dismiss a third successive complaint that alleged it tied the sales of Maps, Routes and Places application programming interface (API) services to one another. A basic tying claim involves a seller leveraging its market power in one product (the “tying” product) to force sales and gain market share over a different product (the “tied” product). Following the dismissal of an initial complaint filed in 2022, the plaintiffs filed an amended complaint alleging Google created a “three-way” tying arrangement by conditioning the sale of one API service (e.g., Maps) on the required purchase of the two other services (e.g., Routes and Places) through its contractual terms of service. The plaintiffs alleged that the tying product could be any of the three APIs and that Google had market power in all three. Whichever plaintiffs bought first was the tying product, and the other two were tied products – allegedly locked in by forced sale or prohibition on use of competitor APIs as a condition of the first sale. The court granted Google’s motion to dismiss because the plaintiffs did not explain how a product could be both a tying product (requiring market power) and the tied product (lacking market power) depending simply on the order of the sales. In their second amended complaint, the plaintiffs abandoned the three-way tying claim, instead bringing a basic tying claim with Maps as the tying product and Routes and Places as the tied products. Google has again moved to dismiss the complaint.

    THE DETAILS

    • Maps, Routes and Places APIs are interrelated but separately licensed services that appear alongside each other in mapping applications like Google Maps.
    • In response to the first amended complaint, Google argued that the plaintiffs did not explain how a product could be both a tying and a tied product depending on the order of sale, given the inherent conflicts in market power required of each.
    • Google also argued that it had broad rights to dictate the terms of use and display of its mapping services, including a right to protect and control user experience through restricting use of its mapping API services in conjunction with or in proximity to non-Google mapping API services, relying in part on a case called Sambreel. 906 F. Supp. 2d at 1073 (S.D. Cal. 2012).
    • The US Department of Justice Antitrust Division (DOJ) intervened, filing a Statement of Interest urging the court to reject Google’s interpretation of Sambreel as establishing an “unqualified right” over the use and display of its services. The DOJ did not take a position on whether the claim should survive otherwise.
    • The court agreed with the DOJ, holding that Google’s interpretation of “control” is too broad and could justify any tying arrangement as an exercise of a supplier’s right to determine or dictate the terms on which its product or service was used.
    • The court also found that the plaintiffs failed to explain how a product could be either a tying or a tied product depending on purchase order, given it is necessary to show market power in tying products and lack of market power in tied markets, or how Google allegedly leveraged its products that way here.
    • Notably, the court said that a three-way tying theory might be viable in some instances, but it was “unclear” how. The court acknowledged an ongoing litigation that allowed a tying claim to proceed where purchase order determined which product was the tying product and which was the tied product despite the “inconsistency” of the allegation. That case is in early stages, and it remains to be seen whether the claim will survive summary judgment.
    • Despite the opportunity to do so, the Google plaintiffs did not attempt to reprise their three-way tying claim in their second amended complaint. They instead pivoted to a basic tying claim with Maps API as the tying product and Routes and Places APIs as tied products.
    • Google has again moved to dismiss the complaint, stating that the plaintiffs mischaracterize Google’s terms of service and its enforcement; that the plaintiffs have not alleged any coerced sales of Google API services; and that the plaintiffs did not sufficiently plead API product markets or market power. That motion is pending.

    WHY IT MATTERS

    • The court here acknowledged three-way tying claims might be viable in some circumstances. The plaintiffs changing course in their second amended complaint means this will not be the test case to find out how.
    • The DOJ’s Statement of Interest made clear its stance that sellers do not have unqualified rights over the use of their products. The court’s adoption of the DOJ’s position shows that courts, in addition to agencies, are closely scrutinizing the interactions between the antitrust laws and product licensing. The court went further to say these licensing and control rights “particularly in technology context” do not trump antitrust laws.
    • All companies – with tech firms under particular scrutiny– should consider the antitrust laws when establishing licensing and services agreements governing product use. As this case shows, litigation on these issues can be protracted and expensive even when largely successful.
    Authors

    Gregory E. Heltzer

    Partner

    Washington, DC

    Lisa P. Rumin

    Partner

    Washington, DC

    More insights
    Endnotes

  • Revision of the AIFM and UCITS Directives

    Revision of the AIFM and UCITS Directives

    ARTICLE / CLIENT ALERT

    Revision of the AIFM and UCITS Directives

    March 4, 2024

    Read time: 2 min

    Key takeaways
    Overview

    Reviewed versions of the AIFM and the UCITS Directive have been fixed and shall come into force by the middle of 2024. Member states will then have a period of two years for implementation. Amendments have been drafted especially with regard to delegation, loan originating funds and liquidity management tools. This article summarizes the main changes and gives an overview on the further procedure.

    Read full article here. (German)

    In depth
    Authors

    Frank Müller

    Partner

    Frankfurt

    More insights

  • CMS Finalizes Important Changes to Medicare Enrollment Requirements for Hospice, Home Health Providers

    CMS Finalizes Important Changes to Medicare Enrollment Requirements for Hospice, Home Health Providers

    ARTICLE / CLIENT ALERT

    CMS Finalizes Important Changes to Medicare Enrollment Requirements for Hospice, Home Health Providers

    February 28, 2024

    Read time: 6 min

    Key takeaways
    Overview

    The US Centers for Medicare & Medicaid Services (CMS) finalized important changes to the Medicare enrollment regulations applicable to hospices and home health agencies (HHAs), including increasing the level of screening that hospice providers are subject to and limiting a Medicare-enrolled hospice’s ability to change majority ownership to once every 36 months.

    In depth

    Background

    To receive Medicare reimbursement for providing services to Medicare beneficiaries, healthcare providers and suppliers are required to enroll in the Medicare program. Medicare providers and suppliers are required to continuously comply with enrollment regulations applicable to the specific Medicare provider or supplier type, including making any necessary updates to the provider or supplier’s enrollment file in order to receive Medicare reimbursement.

    These regulations are intended to promote program integrity and ensure that Medicare providers and suppliers are operating in accordance with program requirements. CMS and Medicare Administrative Contractors (MACs) are permitted to take proactive action against providers and suppliers engaging (or potentially engaging) in fraudulent or abusive behavior that present a risk of harm to Medicare beneficiaries or that are otherwise unqualified to furnish Medicare services or items. Consistent with these continuing policy goals, CMS finalized changes to the Medicare enrollment regulations for home health and hospice providers in the CY 2024 Home Health Prospective Payment System Final Rule. Please see our prior summary of additional recent Medicare enrollment changes from other CMS final rules for more information.

    Under current Medicare enrollment regulations, HHAs are subject to what is referred to as a 36-month rule. If an HHA undergoes a change in majority ownership within 36 months after the HHA’s initial enrollment in Medicare or within 36 months of the HHA’s most recent change in majority ownership, the HHA’s Medicare provider agreement (and billing privileges) cannot be transferred to the HHA’s new owner. The new owner must instead enroll in Medicare as a new HHA and obtain a state survey or accreditation from an approved CMS accreditation organization. This is a time- and resource-intensive process that can serve as a barrier to a change in majority ownership of a Medicare-enrolled HHA.

    Key Changes to Medicare Enrollment for Home Health and Hospice Providers

    Due to CMS’s increased concerns about program integrity with respect to hospices, CMS finalized changes to the Medicare enrollment regulations that are intended to scrutinize hospice owners and limit hospices’ ability to change ownership.

    Applying the 36-Month Rule to Hospices

    In the CY 2024 home health rule, CMS finalized the expansion of the 36-month rule to apply to hospices undergoing a change in majority ownership. A ‘‘change in majority ownership’’ occurs when an individual or organization acquires a direct ownership interest of more than 50% in a hospice during the 36 months following the hospice’s initial enrollment or most recent change in majority ownership (including an acquisition of majority ownership through the cumulative effect of asset sales, stock transfers, consolidations or mergers). CMS indicated that it made this change to prevent hospices being sold after Medicare enrollment or a prior purchase to avoid scrutiny of the hospice’s new ownership. CMS was concerned that hospice ownership changes do not typically result in a state survey or accreditation review, similar to HHAs. These types of surveys can ensure that the hospice is operating in compliance with Medicare conditions of participation. The four existing exceptions to the 36-month rule that apply to HHAs will also apply to hospices.

    Hospices Designated as High-Risk Providers

    Certain enrolled provider types are subject to heightened scrutiny based on the level of risk the provider or supplier type poses to the Medicare program. For all providers, the MAC is required to conduct basic screening, which includes verifying that the provider meets all applicable federal regulations and state requirements for its provider type, that the provider is appropriately licensed in the state(s) of operation and that the provider meets the enrollment criteria for its provider type.

    Prior to this home health final rule, hospices were a provider in the moderate-risk screening category, which required a site visit in addition to the basic screening. In the home health rule, CMS includes initially enrolling hospices and those submitting applications to report a new owner as part of the high-risk category. MACs will now require hospice owners with 5% or greater direct or indirect ownership to submit fingerprints for a criminal background check.

    CMS temporarily waived the requirement for fingerprint-based criminal background checks during the COVID-19 public health emergency (PHE). CMS will now perform fingerprint-based criminal background checks for high-risk providers and suppliers (including both hospices and home health providers) that initially enrolled during the PHE upon their revalidation.

    Provisional Periods of Enhanced Oversight

    At its discretion, CMS can subject new providers and suppliers to a provisional period of between 30 days and one year, during which the provider or supplier will be subject to enhanced oversight. CMS has previously implemented these procedures through subregulatory guidance. These provisional periods of enhanced oversight may include, but are not limited to, prepayment review and payment caps. For example, CMS implemented a period of enhanced oversight with respect to newly enrolled HHAs’ requests for anticipated payments. . In addition, effective July 2023, CMS established a provisional period of enhanced oversight for new hospices located in Arizona, California, Nevada and Texas.

    In the home health rule, CMS finalized regulations to clarify the definition of “new” provider or supplier for purposes of a provisional period of enhanced oversight. Specifically, a “new” provider or supplier includes:

    • Newly enrolling Medicare providers or suppliers, including providers that must enroll as new providers following a change in majority ownership
    • Certified providers undergoing a change of ownership, including providers that qualify for an exception from the change in majority ownership requirements
    • Providers or suppliers, including HHAs and hospices, undergoing a 100% change of ownership via a change of information request

    The effective date of the provisional period of oversight for a new provider is the date on which the new provider or supplier submits its first claim to Medicare (rather than, for example, the date the first service was performed or the effective date of the ownership change). This change is also intended to ensure that the new provider or supplier cannot avoid the provisional oversight period by delaying billing until the period’s expiration date.

    Conclusion

    In the most recent regulatory rulemaking cycle, CMS continued the trend of strengthening its program integrity authority. These new enrollment requirements significantly affect new and existing Medicare-enrolled hospices, which will be subject to increased scrutiny upon initial enrollment, revalidation and any changes in ownership. The expansion of the 36-month rule in particular could limit a Medicare-enrolled hospice’s ability to change ownership more frequently than once every three years.

    Authors

    Monica Wallace

    Partner

    Chicago

    Caroline Reignley

    Partner

    Washington, DC

    Callee Donovan

    Associate

    Boston

    More insights

  • New Jersey Governor Flip-Flops on Corporate Business Tax Surtax Expiration

    New Jersey Governor Flip-Flops on Corporate Business Tax Surtax Expiration

    ARTICLE

    New Jersey Governor Flip-Flops on Corporate Business Tax Surtax Expiration

    Feb 27, 2024

    Read time: 2 min

    Key takeaways
    Overview

    After months of insisting that he would not allow New Jersey’s 2.5% corporate business tax surtax to be extended – and previously having allowed it to lapse for tax years beginning on January 1, 2024 – New Jersey Governor Phil Murphy is now proposing that the surtax be revived for companies earning profits that exceed $10 million a year (up from the prior threshold of $1 million). The proposal appears to apply retroactively to January 1, 2024.

    This will cause New Jersey to once again have the highest corporate income tax rate in the nation at 11.5%. According to the New York Times, Governor Murphy is selling the revival of the surtax as a “corporate transit fee” because the extra revenue will be earmarked for New Jersey Transit.

    The governor’s proposed flip-flop is expected to receive significant pushback from the business community. The New Jersey Chamber of Commerce, which has already called the governor’s proposal a “nightmare scenario for New Jersey,” has indicated that it will be meeting with the Murphy administration and legislative leaders to voice their opposition.

    Authors

    Stephen P. Kranz

    Partner

    Washington, DC

    Michael J. Hilkin

    Partner

    New York – One Vanderbilt Avenue

    More insights
    Endnotes

  • FDA Finalizes Revised Medical Device Quality System Requirements, Issues Remote Regulatory Assessments Guidance

    FDA Finalizes Revised Medical Device Quality System Requirements, Issues Remote Regulatory Assessments Guidance

    ARTICLE / CLIENT ALERT

    FDA Finalizes Revised Medical Device Quality System Requirements, Issues Remote Regulatory Assessments Guidance

    February 27, 2024

    Read time: 7 min

    Key takeaways
    Overview

    The US Food & Drug Administration (FDA) recently issued two critical policies aimed at harmonizing medical device quality requirements with international standards and enhancing medical device regulatory compliance oversight. On February 2, 2024, the FDA issued the first of these policies: a final rule amending the medical device Current Good Manufacturing Practice requirements of the Quality System Regulation (QSR) to align with the ISO 13485:2016 international standard. Notably, the new standard and requirements under the final rule will not take effect until February 2, 2026.

    The second policy is a draft guidance regarding remote regulatory assessments (RRAs) to provide information on the FDA’s continued use of RRAs to conduct remote evaluations of FDA-regulated entities. Together, these developments underscore the FDA’s commitment to streamline global medical device compliance and modernize its regulatory oversight mechanisms.

    In depth

    More on the QMSR Final Rule

    The FDA’s final rule amending the QSR harmonizes US regulations with ISO 13485:2016 to create the Quality Management System Regulations (QMSR), facilitating a more streamlined approach for global market access and removing redundant efforts to comply with the similar QSR and ISO standards. Previously, domestic and international device manufacturers had the onerous burden of meeting both standards, which created a hurdle for US companies marketing abroad and for foreign companies marketing in the United States. This amendment is intended to enhance the quality and safety of medical devices and reduce compliance burdens for device manufacturers by integrating internationally recognized best practices into the current US regulatory framework found at 21. C.F.R. Part 820.

    The FDA has also proposed incorporating ISO 13485:2016 by reference into the federal regulations governing medical devices. Like the QSR, the QMSR will only apply to manufacturers of finished devices, as the FDA did not extend the scope of the final rule to apply the QMSR requirements to manufacturers of components or parts of devices, third-party servicers or refurbishers.

    Manufacturers are encouraged to assess and adapt their quality management systems to ensure compliance with the updated requirements, thereby improving operational efficiency and product quality. Meanwhile, the FDA will be making efforts to improve its information technology systems, develop an inspection process, review and assess compliance with the new requirements, and continue to revise regulations to meet ongoing needs. The FDA anticipates that new requirements will ultimately save the medical device industry an estimated $532 million to $554 million.

    Key changes include the following:

    • Emphasis on the incorporation of QSR standards not required by ISO 13485:2016 to remain consistent with the current regulatory framework. The QMSR incorporates key elements from the QSR that are not required by the broader ISO standard, such as complaint records, device labeling and packaging controls. This inclusion ensures that the QMSR remains consistent with the Federal Food, Drug, and Cosmetic Act (FD&C Act) and FDA regulations by addressing areas where the ISO standard may be less specific, such as the inspection of labeling and packaging by manufacturers and maintaining detailed complaint records.
    • More flexibility for design controls to ensure product efficacy and safety. Unlike the QSR, whereby an individual with direct responsibility over the design stage did not have to be included in the design review, the QMSR requires that individuals concerned with the design stage under review, as well as other specialist personnel, be included in the design review. However, manufacturers can choose whom they include in each stage of design review.
    • Improved supply management and control measures. Manufacturers will now be required to maintain various internal reports for FDA inspection, such as management reviews, internal quality audit reports and supplier audit reports that were not previously required for recordkeeping purposes under the QSR.
    • Commitment to maintaining the FDA’s standard of oversight. The FDA may continue to accept audit reports from the Medical Device Single Audit Program (MDSAP), a voluntary program whereby third parties conduct audits of device manufacturers and certify their performance according to ISO standards as a substitute for routine FDA inspections. Notably, the final rule clarifies that certificates from third-party audits will not serve as a substitute for FDA inspections, nor will the FDA issue those certificates to signify a successful inspection. This policy reflects the FDA’s commitment to continuing its own standard of oversight. The FDA will continue to incorporate input from stakeholders regarding its new inspection approach.

    RRA Draft Guidance

    The FDA also released draft guidance titled Conducting Remote Regulatory Assessments, which outlines the procedures, expectations and implications of RRAs – tools introduced during the COVID-19 pandemic to allow the FDA to conduct remote regulatory oversight. The FDA’s revised draft guidance on RRAs represents a significant shift toward leveraging digital technologies for regulatory oversight. This guidance outlines the following framework for conducting assessments remotely:

    • RRAs are defined as evaluations of FDA-regulated establishments and/or their records and are conducted entirely remotely. The assessment can be either mandatory or voluntary, with specific guidelines on how the FDA will initiate requests and what establishments can expect during these assessments. Manufacturers can expect FDA requests for records similar to those made during an onsite inspection, virtual information review meetings, live streams and/or pre-recorded videos to examine company operations, etc.
    • Manufacturers will need adequate IT infrastructure for live streaming, video conferencing, necessary translation and secure data transmission to support and facilitate an RRA. Otherwise, the FDA may choose to terminate the RRA and use other available tools.
    • RRAs are not an inspection, nor do they limit or replace forms of communication the FDA already relies on to gather information, such as applicant request letters, registration confirmations, meetings, product submission, application assessments and follow-up communications during outbreaks or other emergencies. Rather, RRAs are meant to help the FDA fulfill its regulatory responsibilities remotely when there are travel or other restrictions. The use of RRAs is at the FDA’s discretion.
    • Upon completion of an RRA, the FDA may conduct a closeout meeting, issue observations and expect responses or corrective actions from the establishment. The guidance clarifies that RRA observations are not final FDA actions but may inform subsequent FDA actions, including inspections.

    Embracing RRAs can reduce the regulatory burden on manufacturers while maintaining rigorous standards for device safety and efficacy.

    Next Steps

    Manufacturers must navigate these updates with strategic foresight and will have two years to update their compliance programs to meet the new QMSR standards. Alignment with ISO 13485:2016 requires a thorough review of current quality management systems, while the continued use of RRAs to assess compliance with the new requirements demands readiness for remote engagements with the FDA. Both policies highlight the importance of technological integration and global standards compliance in the regulatory strategy of medical device companies.

    Manufacturers should ensure they have the necessary technological capabilities to support participation in RRAs and develop internal protocols to prepare for and respond to potential RRA requests.

    The FDA’s recent policies reflect a broader trend toward global harmonization and digital transformation in regulatory practices. Manufacturers should (1) analyze their current systems to probe for gaps and ensure they are able to provide continuous compliance with the new requirements under QMSR and (2) develop an implementation plan for those updates. By staying ahead of these regulatory changes, companies can position themselves as leaders in the highly competitive and rapidly evolving medical device industry.

    For more information on the FDA’s amendments, please contact Jamie Ravitz, Paul Gadiock, Jeff Weinstein, Rachel Gartner, Marissa Hill Daley or any other member of McDermott’s Food, Drug & Medical Device Regulatory Practice Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    More insights

  • FDA Proposes Rule to Update Clinical Trial Data Monitoring

    FDA Proposes Rule to Update Clinical Trial Data Monitoring

    ARTICLE / CLIENT ALERT

    FDA Proposes Rule to Update Clinical Trial Data Monitoring

    February 27, 2024

    Read time: 7 min

    Key takeaways
    Overview

    On February 13, 2024, the US Food and Drug Administration (FDA) issued draft guidance entitled Use of Data Monitoring Committees in Clinical Trials (Draft Guidance). It provides sponsors and others involved in clinical trial management with recommendations for determining when to engage a data monitoring committee (DMC) for trial monitoring. It also provides recommended procedures and other considerations for DMCs. Once the Draft Guidance is finalized, it will supersede FDA’s March 2006 guidance entitled Establishment and Operation of Clinical Trial Data Monitoring Committees.

    In depth

    Background on DMCs

    A DMC (often referred to as a data safety monitoring committee) is a group of individuals with relevant clinical, scientific, statistical or other expertise. This group regularly reviews human-subject data accumulating from a clinical trial and provides recommendations to the sponsor on whether to continue, modify or suspend the clinical trial. In certain circumstances, a DMC may also provide recommendations regarding operational matters based on noncomparative safety and efficacy data.

    Even though sponsors are required to use DMCs only for certain emergency research, the use of DMCs has increased in many areas beyond the historic norm of diseases involving serious morbidity or mortality. (21 CFR 50.24(a)(7)(iv) sets forth the exception for the requirement to obtain informed consent for a clinical trial in an emergency setting. One condition for such exception is the establishment of an independent DMC to oversee the clinical trial.) FDA notes that DMCs are now being used for modest-sized trials, to implement certain adaptive clinical trial designs, and to oversee entire clinical development programs (as opposed to single clinical trials). In part, the Draft Guidance appears to be an effort by FDA to update its recommendations for DMCs given the significant changes in the use of DMCs that have occurred since FDA released its 2006 guidance.

    Relationship Between DMCs and Other Oversight Groups

    The Draft Guidance addresses the specific relationships DMCs have with other groups that may be involved in a clinical trial, including an institutional review board, a clinical trial steering committee, an endpoint assessment/adjudication committee, clinical site monitors, entities reviewing safety reporting, and an adaptation committee. DMCs are often the only group with access to the accumulating unblinded safety and efficacy data of a clinical trial. (FDA considers data to be unblinded when it is reviewed by treatment group (e.g., A versus B), even when the groups are identifiable.) Generally, access to such data is not granted to other groups involved in a clinical trial to avoid biasing the outcome of the trial by inappropriately influencing trial conduct or the approach to analyses. DMCs, in contrast, have access to this data in order to:

    • Monitor the safety data
    • Advise the sponsor on the safety of the interventions in trial subjects
    • Monitor interim effectiveness results to determine if they support a benefit or futility
    • Help ensure scientific merit and integrity of the clinical trial

    DMCs should remain independent of sponsors and therefore should not have a significant financial connection to a sponsor. Additionally, DMCs should not be involved in the design or conduct of the trial. A DMC’s independence is important because it:

    • Ensures the sponsor’s interests do not inappropriately influence the DMC
    • Enhances the DMC’s objectivity and limits the possibility of bias
    • Preserves the sponsor’s ability to make modifications to a clinical trial without introducing bias
    • May help prevent a conflict of interest for the sponsor by keeping them in a fully blinded state

    How independence is defined is important. Too narrow a definition may prohibit knowledgeable researchers from being DMC members.

    Overview of the Draft Guidance

    Use of DMCs

    In the Draft Guidance, FDA provides sponsors with considerations for determining whether to use a DMC for any given clinical trial. Such considerations include:

    • Whether the use of a DMC is practical for a particular clinical trial
    • The extent of investigator, study site or other experience in a therapeutic area
    • The participation of subjects from a vulnerable population

    However, FDA states that it strongly recommends using a DMC whenever trial subjects are at risk of serious morbidity or mortality, even if one of these factors is not relevant.

    Considerations for Establishing and Operating DMCs

    While sponsors are responsible for establishing DMCs, the DMC should remain independent of the sponsor and the trial conduct. The Draft Guidance describes how to successfully achieve this independence, makes suggestions for DMC composition and outlines training considerations for DMC members.

    FDA recommends that DMCs include:

    • Individuals with expertise in conducting clinical trials
    • Clinicians with relevant clinical specialty expertise
    • A biostatistician
    • Members with experience serving on DMCs
    • Members with FDA regulatory expertise

    The agency also recommends considering the inclusion of an individual with expertise in informatics and technology. As clinical trials proliferate in the field of artificial intelligence (AI), it will increasingly be wise to include a member with computational or other relevant experience in keeping with the spirit of the Draft Guidance, although the Draft Guidance does not address this point.

    Importantly, DMC members should be screened for both financial and intellectual conflicts of interest or bias. For example, DMC members should not have any ongoing financial relationship with the commercial sponsor of the clinical trial (or such sponsor’s direct competitors). Additionally, individuals should not have intellectual conflicts of interest that may render them unable to evaluate the clinical trial data objectively because they have strong views on the relative merits of the investigational product or intervention.

    FDA also recommends establishing a DMC charter that states the DMC’s obligations, responsibilities and standard operating procedures. Either the DMC itself or the sponsor (with the DMC’s input) may prepare the charter. The charter should address:

    • Specific information about the composition of the DMC
    • Meeting information, schedule and format
    • Planned analyses by the DMC
    • The protection of data, where applicable
    • How the confidentiality of the data will be maintained

    Addressing DMC Recommendations

    The Draft Guidance states that a sponsor must investigate if the DMC makes a recommendation to the sponsor about a clinical trial based on a potential relationship between an increased rate of serious unanticipated adverse events and the investigational product. If the investigation leads the sponsor to conclude that there is a reasonable possibility that the event is associated with the product, the sponsor must inform FDA of these findings. FDA also recommends that sponsors notify the agency of all DMC recommendations that are related to an investigational product’s safety, irrespective of whether any adverse events underlying the recommendation meet the definition of “serious.”

    While DMCs may make recommendations to sponsors regarding whether to continue, modify or stop a clinical trial, the final decision as to whether to terminate any clinical trial belongs to the sponsor.

    Next Steps

    You should evaluate the potential impact of the Draft Guidance and submit comments by April 15, 2024.

    For more information on FDA’s Draft Guidance, contact Jamie Ravitz, Jiayan Chen, Jennifer Geetter, Paul Gadiock, Jeff Weinstein, Rachel Gartner, Marissa Hill Daley or any other member of McDermott’s Food, Drug & Medical Device Regulatory Group or Digital Health Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Jennifer S. Geetter

    Partner

    Washington, DC

    Jiayan Chen

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    Jeff Weinstein

    Counsel

    Washington, DC

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    More insights

  • Gender-Affirming Benefits: Best Practices for Group Health Plans

    Gender-Affirming Benefits: Best Practices for Group Health Plans

    ARTICLE / CLIENT ALERT

    Gender-Affirming Benefits: Best Practices for Group Health Plans

    February 26, 2024

    Read time: 7 min

    Key takeaways
    Overview

    Our webinar, “Gender-Affirming Benefits: Best Practices for Group Health Plans,” reviewed legal developments in the shifting landscape of transgender benefits and best practices that group health plans should keep in mind as they evaluate how to cover transgender care. Watch the recording here.


    I. Introduction

    Federal legislative and regulatory activity related to employer-sponsored group health plans shows no signs of slowing, particularly with the issuance of interpretive guidance regarding the transparency and surprise-billing rules enacted by the Consolidated Appropriations Act, 2021. States also have been active, both in their regulation of licensed health-insurance carriers and by aggressively seeking ways to regulate self-funded arrangements at the margins. The latter trend has already manifested in laws governing reproductive health, which received significant attention following the US Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization. (For more information on the impact of the Dobbs decision, visit McDermott’s Post-Roe Resource Center.) Now, attention has also turned to whether − and to what extent − group health plans must cover gender-affirming medical or surgical treatments (gender-affirming care), especially regarding minors.

    Group health plan sponsors encounter coverage of gender-affirming care differently, depending on whether they purchase insurance or self-fund their health benefits. Fully insured plans must follow applicable state mandates, while self-funded plans generally have more flexibility in plan design. However, employers will struggle with certain state laws related to travel for the purpose of gender-affirming care, irrespective of plan funding. The issues they encounter are similar to the questions concerning reproductive health that have followed the Dobbs decision.

    The World Health Organization defines gender-affirming care (which incudes but is not limited to gender-reassignment surgery) to include a range of social, psychological, behavioral and medical interventions “designed to support and affirm an individual’s gender identity” when it conflicts with the gender they were assigned at birth. Interventions fall along a continuum, from counseling, to changes in social expression, to medications such as hormone therapy.

    The World Professional Association for Transgender Healthcare, an influential standard-setting organization, publishes internationally accepted clinical guidelines for gender-affirming care, the most recent of which addresses for the first time the treatment of adolescents, providing that an inquiry into whether gender-affirming care is appropriate must be determined case by case, based on an assessment of emotional and cognitive maturity.

    II. Applicable Laws

    The ERISA Preemption Doctrine

    The Employee Retirement Income Security Act (ERISA) bars the application of “any and all State laws insofar as they now or hereafter relate to any employee benefit plan … ” The term commonly used for this broad prohibition against state involvement in ERISA plans is “ERISA preemption” of state law. There are some exceptions to ERISA preemption of state law, primarily allowing states to enforce insurance, banking and securities laws of general application. Thus, for example, a state may not be able to regulate a benefit plan directly, but within limits it can regulate an insurance company that insures plan benefits, which in turn affects fully insured plans. Any state law requiring or barring coverage of gender-affirming care would likely be preempted for self-funded ERISA plans, although it may impact fully insured plans. However, state criminal laws of general application are not preempted.

    Section 1557 of the Affordable Care Act

    Section 1557 of the Affordable Care Act (ACA) prohibits discrimination on the basis of race, color, national origin, sex, age or disability in a health program or activity, any part of which receives federal financial assistance.  A 2022 proposed regulation issued by the US Department of Health and Human Services (HHS) would modify prior to make clear that discrimination based on gender identity is prohibited. This position is in accord with the Supreme Court’s ruling in Bostock v. Clayton County, Georgia, which held that the references to “sex” in Title VII of the Civil Rights Act include sexual orientation and gender identity. Where gender dysphoria qualifies as a disability, restrictions that prevent individuals from receiving medically necessary care based on a diagnosis or perception of gender dysphoria may also violate Section 504 and the Americans with Disabilities Act.

    The Mental Health Parity Act

    The Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) generally requires that group health plans and group health insurance issuers ensure that the financial requirements and treatment limitations applicable to mental health/substance use disorder (MH/SUD) benefits are no more restrictive than those applicable to medical surgical (M/S) benefits (e.g., more restrictive lifetime or annual dollar limits, financial requirements or treatment limitations) and that there are no separate financial requirements or treatment limitations applicable to MH/SUD benefits.

    Gender dysphoria is generally considered a mental-health condition; thus, MHPAEA might impose limits on cost-sharing for gender-affirming care to match the limits imposed on a plan’s M/S benefits.

    State Laws Protecting Access to or Barring Gender-Affirming Care

    States have increasingly passed laws to penalize parents aiding minors in accessing gender-affirming care, permitting individuals to file for damages against providers who violate such laws, limiting insurance coverage or payment for gender affirming services, or prohibiting the use of state funds for such services. Other states have established “shield” laws, which protect access to gender-affirming care. (For a survey of gender-affirming care state law, see KFF’s Policy Tracker: Youth Access to Gender Affirming Care and State Policy Restrictions.

    The Health Insurance Portability and Accountability Act (HIPAA)

    State laws penalizing or discouraging gender-affirming care may seek to gain access to health records of individuals receiving such care. This information is protected health information (PHI) under HIPAA. HIPAA permits, but does not require, covered entities and business associates to disclose PHI without individual authorization when such disclosure is required by law. Examples of such requirements include, but are not limited to, information requests in court-ordered warrants, subpoenas, or summons issued by a court or grand jury. States may attempt to leverage this “required by law” exception to PHI disclosures under HIPAA to impose sanctions or penalties. HHS issued a proposed rule that would bar this approach in the context of reproductive health, and it has also expressed the view in sub-regulatory guidance that this use does not meet the “required by law” definition.

    III. Approaches to Coverage of Gender-Affirming Care

    Group health plan sponsors, third-party administrators and other health plan service providers must determine how best to navigate potentially conflicting and rapidly shifting laws, regulations, and changing cultural norms and clinical standards relating to gender-affirming care, especially in relation to minors:

    • Fully insured plans must follow the terms of underlying group health insurance policies, which are required to follow applicable state law.
    • Although self-funded plans have greater plan-design latitude, categorically denying access to gender-affirming care may violate Section 1557 of the ACA. This poses a challenge for  self-funded plans that cover individuals in multiple states, including those that have restricted or prohibited gender-affirming care. While ERISA should preempt state civil laws on the subject, the extent to which preemption extends to state criminal laws is unclear.
    • Self-funded plans may implement medical travel benefit plans to supplement their coverage in states that restrict or prohibit gender-affirming care, similar to the increase in medical travel benefits post-Dobbs.
    • Laws and regulations regarding gender-affirming care for minors are still shifting, although federal policy and current clinical standards appear to favor covering gender-affirming care for minors on a case-by-case basis where medically necessary.

    Group health plan sponsors, third-party administrators and other health plan service providers should understand the costs of their plan design options and assess gender-affirming care coverage, especially in light of conflicting federal and state laws, increased litigation in several states (e.g., Texas), regulatory guidance, and increased enforcement of ERISA fiduciary duties with respect to health and welfare plans. Please contact the authors or your regular McDermott lawyer if you have any questions regarding gender-affirming care coverage and the implications for your organization.

    In depth
    Authors

    Sarah G. Raaii

    Partner

    Chicago

    More insights